CRL
Charles River Laboratories InternationalANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
The stock trades below the packet’s median analyst target of $237.79. Reaffirmed guidance, solid DSA bookings, completed divestitures, and strategic AI-enabled collaborations could support improving margins and a moderate rerating.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
A director reported a 75,000-share open-market sale at $225 [#SEC-FORM4-2026-07-01].
Momentum
90
Value
62
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $238.00 · Bull $255.00 · Bear $195.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $237.79
Why
Momentum90 · Δ7d +0.7
Value62 · Δ7d +0.2
Sentiment52 · Δ7d +4.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
90
26% active weight
Current posture
7d trendImproving
Δ7d
+0.7
Δ21d
+4.7
Value
62
39% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.1
Sentiment
52
34% active weight
Current posture
7d trendImproving
Δ7d
+4.5
Δ21d
+12.1
Why this grade
Composite grade A. Momentum 90.1 / Value 61.7 / Sentiment 52.5
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$10.58B
Beta
1.63
Shares Out
48.17M
P/E (TTM) · Derived
-75.4
P/S (TTM)
2.55
P/FCF (TTM)
18.86
Rev YoY
+1.2%
EPS YoY
-160.5%
Gross Margin
+31.3%
Op Margin
+3.5%
Net Debt
$2.42B
Current Ratio
1.36
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology